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Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease, mostly
idiopathic and with palliative treatment. Neuropathologically, it is characterized by
intracellular neurofibrillary tangles of tau protein and extracellular plaques of amyloid
β peptides. The relationship between AD and neurogenesis is unknown, but two
facts are particularly relevant. First, early aggregation sites of both proteinopathies
include the hippocampal formation and the olfactory bulb (OB), which have been
correlated tomemory and olfactory deficits, respectively. These areas are well-recognized
integration zones of newly-born neurons in the adult brain. Second, molecules, such
as amyloid precursor protein (APP) and presenilin-1 are common to both AD etiology
and neurogenic development. Adult neurogenesis in AD models has been studied
in the hippocampus, but only occasionally addressed in the OB and results are
contradictory. To gain insight on the relationship between adult neurogenesis and
AD, this work analyzes neurogenesis, neurodegeneration, interneuron vulnerability, and
amyloid-β involvement in the OB of an AD model. Control and double-transgenic
mice carrying the APP and the presenilin-1 genes, which give rise amyloid β plaques
have been used. BrdU-treated animals have been studied at 16, 30, 43, and 56
weeks of age. New-born cell survival (BrdU), neuronal loss (using neuronal markers
NeuN and PGP9.5), differential interneuron (calbindin-, parvalbumin-, calretinin- and
somatostatin-expressing populations) vulnerability, and involvement by amyloid β have
been analyzed. Neurogenesis increases with aging in the granule cell layer of control
animals from 16 to 43 weeks. No neuronal loss has been observed after quantifying NeuN
or PGP9.5. Regarding interneuron population vulnerability: calbindin-expressing neurons
remains unchanged; parvalbumin-expressing neurons trend to increase with aging in
transgenic animals; calretinin-expressing neurons increase with aging in transgenic mice
and decrease in control animals and neurogenesis is higher in control as compared to
transgenic animals at given ages, finally; somatostatin-expressing neurons of transgenic
mice decrease with aging and as compared to controls. Amyloid β aggregates with
aging in the granule cell layer, which may be related to the particular involvement of
somatostatin-expressing cells.
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INTRODUCTION
Alzheimer’s disease (AD) is the most prevalent
neurodegenerative disease and the main cause of dementia
(Reiman, 2014). It is characterized by cognitive deficits
and nowadays treatments are palliative. Two associated
proteinopathies yield aggregates into the brain: tau protein that
form intracellular neurofibrillary tangles and insoluble forms
of amyloid β (Aβ) peptides that assembles into extracellular
plaques (Goedert and Spillantini, 2006; Ballard et al., 2011).
Neuropathological staging of these deposits show that early sites
of involvement include the OB and the hippocampal formation
(Ohm and Braak, 1987; Braak and Braak, 1991; Braak et al., 2006;
Attems et al., 2014; Braak and Del Trecidi, 2015). These areas
correlate with initial symptoms, namely olfactory (Devanand
et al., 2015) and declarative memory deficits (Jahn, 2013).
Interestingly, the subventricular zone of the lateral ventricles
(SVZ) and the hippocampal subgranular zone (SGZ) were
described as the twomain neurogenic niches giving rise to newly-
born neurons migrating and integrating into the adult olfactory
bulb (OB) and the dentate gyrus (DG) of the hippocampus,
respectively (Altman, 1962; Altman and Das, 1965; Luskin, 1993;
Lois and Alvarez-Buylla, 1994). Decades later, the functional
significance of new neurons integrated into adult OB (Lepousez
et al., 2013) and DG (Deng et al., 2010) is only partially known.
AD and adult neurogenesis are not only linked by common
sites where early pathology occurs and newly-born neurons
integrate in the preexisting circuitry, but share a number of
common molecules to both processes (Kaneko and Sawamoto,
2009; Lazarov and Marr, 2010, 2013; Lazarov et al., 2010;
Mu and Gage, 2011; Winner et al., 2011). Increasing evidence
suggest that molecular players in Alzheimer disease, including
amyloid precursor protein (APP) and presenilin 1 (PS1) and
its metabolites, play a role in adult neurogenesis (Lazarov
and Marr, 2010). Soluble APPα regulate neural progenitor cell
proliferation. Thus, miscleavage of APP would readily influence
on developmental and postnatal neurogenesis, which could
contribute to cognitive deficits characterizing AD (Lazarov and
Demars, 2012). On the other hand, PS1 is not only prominently
expressed in the embryonic brain but is also a crucial regulator
of Notch and Wnt signaling (Winner et al., 2011), key pathways
in neural differentiation. In addition, polymorphisms in the
apolipoprotein E (apoE, the ε4 isoform) gene show the most
significant effects on relative genetic risk of AD. Experiments in
transgenic mice carrying human apoE4 have shown apoptosis
of neural progenitor cells after environmental enrichment
suggesting that apoE4 is somewhat compromising neurogenesis
(Levi and Michaelson, 2007).
Data on neurogenic rate changes in AD models are
quite variable depending on the different transgenic mice,
experimental conditions, and markers analyzed; and, it is
Abbreviations: Aβ, amyloid β; AD, Alzheimer’s disease; APP, amyloid precursor
protein; BrdU, bromodeoxyuridine; CB, calbindin; CR, calretinin; DG, dentate
gyrus; ePL, external plexiform layer; GL, glomerular layer; GrL, granule cell layer;
iPL, internal plexiform layer, MOB, main olfactory bulb; NeuN, Fox3-NeuN; OB,
olfactory bulb; PS1, presenilin 1; PV, parvalbumin; SGZ, subgranular zone; SST,
somatostatin; SVZ, subventricular zone; TG, transgenic; WT, wild type.
not always obvious to distinguish it from changes due
to physiological aging (Lazarov and Marr, 2010; Winner
et al., 2011). Data in the model used in the present study
(APPswe/PS11E9) show reduced hippocampal neurogenesis
(Verret et al., 2007; Niidome et al., 2008). This impairment
in neurogenesis take place early in life long before amyloid
deposition suggesting that the decrease of neurogenic rate
may be a contributor factor rather than a result of neural
dysfunction (Demars et al., 2010). Interestingly, the reduction in
neuroblasts, as confirmed by quantitative Western blot analysis
of doublecortin content, was restricted to the hippocampal but
not to the OB neurogenic system (Zhang et al., 2007).
Data from different authors and our previous results indicate a
differential interneuron vulnerability in postmortem tissue from
Alzheimer’s patients and in transgenic mice model (Fonseca and
Soriano, 1995; Solodkin et al., 1996; Brady and Mufson, 1997;
Leuba et al., 1998; Iritani et al., 2001; Saiz-Sanchez et al., 2010,
2012, 2013, 2015, 2016).
Therefore, the present study aims at characterizing the
neurogenic process in the OB of APP/PS1 mice by analyzing
the neurogenic and neurodegeneration rates and the role Aβ in
the survival of new and preexisting interneuron populations.
MATERIALS AND METHODS
Experimental Animals
For this study, 20 female hemizygous double transgenic mice
(B6C3-Tg-APPswe, PSEN1dD9-85Dbo/J) model of AD and 20
female non-carrier mice have been used (004462, The Jackson
Laboratory, USA). These transgenic mice express a chimeric
mouse/human APP (Mo/HuAPP695swe) and a mutant human
presenilin 1 (PS1-dD9), each controlled by independent mouse
prion protein (PrP) promoter elements (Jankowsky et al., 2001,
2004). The APPswe/PSEN1dD9 (APPxPS1) mouse model is
characterized by increasing Aβ levels with aging (Jankowsky
et al., 2004; Van Groen et al., 2006). Four experimental groups
of five transgenic and five non-carrier animals were stablished
according to survival times (16, 30, 43, and 56 weeks). The
animals were housed on a standard 12/12 h light/dark cycle, at
21◦C with food and water ad libitum. All of the animal research
procedures described herein were in agreement with European
(Directive 2010/63/EU) and Spanish (RD 53/2013) legislation
on the protection of animals used for scientific purposes. All
experiments described were approved by the Ethical Committee
of Animal Research of the University of Castilla-La Mancha
(grant BFU2010-15729).
Bromodeoxyuridine Administration,
Perfusion, and Sectioning
BrdU (5-bromo-2′-deoxyuridine, Fluka, Madrid, Spain)
administration included four i.p. doses (at 2-h intervals) of 10
mg/mL BrdU in phosphate-buffered saline (PBS, 0.15 M NaCl,
0.01 M sodium phosphate pH 7.4) totalizing a dose of 200
mg/kg in 1 day. This dose was employed following previous
results in our laboratory to optimize labeling without increasing
apoptosis (Martínez-Marcos et al., 2000a,b; Martinez-Marcos
et al., 2005; De La Rosa-Prieto et al., 2009). Two week afterwards,
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animals were anesthetized with a combined dose of ketamine
hydrochloride (Ketolar, Parke-Davis, Madrid, Spain, 1.5mL/kg,
75mg/kg), and xylazine (Xilagesic, Calier, Barcelona, Spain,
0.5mL/kg, 10mg/kg) and perfused with saline solution followed
by 4% w/v paraformaldehyde fixative in phosphate buffer (0.1
M sodium phosphate pH 7.2). Brains were postfixed in 4%
w/v paraformaldehyde, cryoprotected in 30% w/v sucrose,
and the olfactory bulbs frontally sectioned (50 µm) using a
freezing sliding microtome (Microm HM450). Sections were
consecutively collected into 96-well-plates and maintained at
4◦C in preserving solution (PBS containing 20% v/v glycerol and
30% v/v ethylene glycol) for further processing.
Immunofluorescence Procedures
Six sections from rostral to caudal OB of each animal were chosen
(separated 400 um) and rinsed overnight with Tris-buffered
saline (TBS; 0.15 M NaCl, 0.05 M Tris, HCl pH 7.6) and
blocked with 10% v/v normal donkey serum (NDS; Vector
Laboratories, Burlingame, CA) in TBS for 60 min at room
temperature. Sections were then incubated overnight with rabbit
anti-amyloid beta (Aβ, 1:250, Cell Signaling, 2454, MA, USA),
goat anti-calretinin (CR, 1:1000, Santa Cruz, sc-11644, CA, USA),
monoclonal mouse anti-calbindin D-28k (CB, 1:5000, Swant,
300, Switzerland), goat anti-somatostatin (SST, 1:1000, Santa
Cruz, sc-7819, CA, USA), goat anti-parvalbumin (PV,1:2000,
Swant, PVG-213, Switzerland), mouse monoclonal PGP9.5
(PGP9.5 13C4/I3C4, 1:1000, abcam, ab8189, Cambridge, MA,
USA), or rabbit anti-NeuN (NeuN, 1:500, abcam, ab104225,
Cambridge, MA, USA) diluted in TBS with 5% v/v normal
goat serum and 0.3% Triton X-100 at 4◦C. Then, sections were
incubated for 2 h at room temperature with Alexas 488, 555, 568,
or 647 anti-multiple species (1:200 in TBS with 2% of normal goat
serum and 0.2% Triton X-100; Invitrogen, Eugene, OR).
Sections were then rinsed with TBS and incubated in ice-cold
paraformaldehyde 4% v/v for 15min. Rinsed again and incubated
in 2N HCL at 37◦ during 1 h. After rinsed several times, sections
were incubated overnight with mouse anti-BrdU (BrdU,1:40,
Dako, M0744, Glostrup, Denmark). Sections were subsequently
incubated for 2 h at room temperature with Alexa 488, anti-
mouse (1:200 in TBS with 2% of normal goat serum and 0.2%
Triton X-100; Invitrogen, Eugene, OR), and counterstained using
DAPI (1µg/ml in TBS, Santa Cruz, SC-3598) for 5 min in
the dark.
Analysis of Labeled Cells
The images of different fluorophores were analyzed using ImageJ
and ZEN software from Zeiss using the profile and ortho
tools of ZEN software. GraphPad Prism R© v.6 (San Diego, CA,
USA) was used for statistical analyses. Kolmogorov–Smirnov and
Wald–Wolfowitz tests were carried out to analyze the normality
and randomness of the sample (P> 0.05). Statistical comparisons
were performed using an unpaired two-tailed t-test, or one-way
or two-way ANOVA followed by Bonferroni and Tukey post-
hoc tests to estimate the significance of differences between
age groups, markers, areas, WT, and TG animals. All data
are represented as mean ± SEM. Differences were regarded as
statistically significant at ∗ or #P < 0.05, ∗∗ or ##P < 0.01, ∗∗∗ or
###P < 0.001, and ∗∗∗∗P < 0.0001.
RESULTS
The aim of the present report has been to study in depth the
relationship between adult neurogenesis and AD by analyzing
neurogenic rate, neurodegeneration, interneuron vulnerability,
and Aβ involvement in the OB of control and transgenic mice
over time. The different layers of the main OB (MOB; Figure 1A)
have been grouped for analysis: granule (GrL) and internal
plexiform (iPL), mitral (ML), and external plexiform (ePL), and
glomerular (GL), and nerve (NL) layers (Figure 1B).
Analysis of BrdU-Labeled Cells
The labeling of BrdU-positive cells was mainly concentrated in
the GrL and GL of control and transgenic animals at different
ages (Figures 1C–F). The analysis of BrdU-labeled cells over
time revealed an increasing trend in the GrL with aging that
was statistically significant between 16 (Figure 1C) and 43
(Figure 1D) weeks in control animals (Figure 1G) [Two-way
ANOVA genotype vs. age: Interaction F(3, 62) = 1.846; p =
0.1482; Age F(3, 62) = 3.220; p = 0.0287; Genotype F(1, 62) =
0.0002612; p = 0.9872]. This trend was not observed in the GL
(Figure 1G) [Two-way ANOVA genotype vs. age: Interaction
F(3, 63) = 0.5647; p = 0.6403; Age F(3, 63) = 2.676; p = 0.0547;
Genotype F(1, 63) = 7.260; p= 0.0090].
Regarding genotype comparison, no clear differences were
observed in the GrL, but in the GL, the number of BrdU-labeled
cells was in general lower in transgenic (Figure 1F) as compared
to control (Figure 1E) animals.
Analysis of NeuN- and PGP9.5-Labeled
Cells
In order to evaluate a possible neuronal loss, two neural markers
have been used in the OB of control and transgenic mice: NeuN
has been used to label neurons in GrL (Figures 2A,B) and GL
(Figures 2E,F), and PGP9.5 in ML (Figures 2C,D) since not all
neural populations are labeled by commercial neural markers (see
Supplementary Figure 1) (Bagley et al., 2007; Bianchi et al., 2014).
Statistical analysis showed no significant changes over time
and genotype or between control and transgenic animals in
the GrL (Figure 2G) [Two-way ANOVA (genotype vs. age):
Interaction F(3, 28) = 0.7079; p = 0.5554; Age F(3, 28) = 0.9086;
p = 0.4494; Genotype F(1, 28) = 0.7859; p = 0.3829], ML
[Two-way ANOVA (genotype vs. age): Interaction F(3, 28) =
2.443; p= 0.0849; Age F(3, 28) = 0.8184; p = 0.4946; Genotype
F(1, 28) = 0.2668; p = 0.6095] or GL [Two-way ANOVA
(genotype vs. age): Interaction F(3, 28) = 2.054; p = 0.1291; Age
F(3, 28) = 2.496; p= 0.0803; Genotype F(1, 28) = 0.005049; p =
0.9439].
Analysis of Interneuron Markers
Calbindin-positive neurons were mostly concentrated in the GL
in both control (Figures 3A,C) and transgenic (Figures 3B,D)
animals. No significant changes were observed with aging
(Figures 3A,B vs. Figures 3C,D) or genotype (Figures 3A,C vs.
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FIGURE 1 | Analysis of neurogenesis in the olfactory bulb by
quantification of bromodeoxyuridine-labeled cells. (A,B) , Nissl staining
of a mouse main olfactory bulb showing all cell layers where analysis has been
carried out. (C–F), examples of bromodeoxyuridine-positive cells at different
ages, in different layers, and in wild type and transgenic animals illustrating
statistical analysis. (G), graphics illustrating the estimation of
bromodeoxyuridine-positive cells/mm3 in control and transgenic animals in
different layers with aging. Calibration bar, 50 µm. White arrows point to
labeled cells. *P < 0.05.
Figures 3B,D) as demonstrated statistically (Figure 3E) [Two-
way ANOVA (genotype vs. age): Interaction F(3, 28) = 1.679;
p= 0.1940; Age F(3, 28) = 1.942; p = 0.1457; Genotype
F(1, 28) = 0.2197; p= 0.6429].
Most parvalbumin-labeled neurons appeared in the ML/ePL
in control (Figures 4A,C) and transgenic mice (Figures 4B,D).
The expression appear to increase from 16 (Figures 4A,B) to 56
(Figures 4C,D) in both control and transgenic animals. Statistical
analysis demonstrated a significant increase from 16 to 43
and 56 weeks in transgenic animals (Figure 4E). No changes
were significant between control and transgenic animals [Two-
way ANOVA (genotype vs. age): Interaction F(3, 28) = 2.026;
p = 0.1331; Age F(3, 28) = 3.617; p = 0.0252; Genotype
F(1, 28) = 0.6551; p= 0.4251].
Calretinin-expressing cells were distributed in the GrL/iPL
and ML/ePL—where positive mitral cells have been included in
the analysis—, but particularly in the GL/NL in both control
FIGURE 2 | Analysis of neurodegeneration in the olfactory bulb by
quantification of NeuN- and PGP9.5-labeled cells. Confocal images
showing NeuN-positive (A,B,E,F) and PGP9.5-positive cells (C,D)
counterstained with DAPI. (G), graphics illustrating the estimation of NeuN-
and PGP9.5-positive cells/mm3 in control and transgenic animals in the
different layers with aging. Calibration bar, 50µm.
and transgenic animals (Figures 5A–F). In the GrL/iPL of
transgenic animals, the expression significantly increased from
30 (Figure 5A) to 56 (Figure 5B) weeks (Figure 5G) [Two-
way ANOVA (genotype vs. age): Interaction F(3, 28) = 3.334;
p = 0.0336; Age F(3, 28) = 1.875; p = 0.1568; Genotype F(1, 28) =
1.481; p= 0.2338]. At 30 weeks, the expression in control animals
was higher as compared to transgenic animals [T-test two tailed
control vs. transgenic: t7 = 2.873; p = 0.0239]. In the ML/ePL
of control animals, the expression significantly decreased from
16 (Figure 5C) to 30, 43, and 56 (Figure 5E) weeks (Figure 5G);
and, at 16 weeks, the expression in control animals (Figure 5C)
was higher as compared to transgenic (Figure 5D) animals
(Figure 5F) [Two-way ANOVA (genotype vs. age): Interaction
F(3, 28) = 3.208; p = 0.0382; Age F(3, 28) = 6.341; p = 0.0020;
Genotype F(1, 28) = 2.021; p = 0.1662] [T-test two tailed control
vs. transgenic: p > 0.05]. In the GL/NL, no significant changes
with aging or genotype were detected (Figures 5A–G) [Two-
way ANOVA (genotype vs. age): Interaction F(3, 28) = 1.031;
p = 0.3940; Age F(3, 28) = 0.7346; p = 0.5402; Genotype
F(1, 28) = 0.1791; p= 0.6754].
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FIGURE 3 | Vulnerability analysis of calbindin-expressing cells in the
olfactory bulb. (A–D), Confocal images showing calbindin-positive cells in
the glomerular layer of control and transgenic animals at different ages. (E),
graphics illustrating the estimation of calbindin-positive cells/mm3 in control
and transgenic animals in the glomerular layer with aging. Calibration bar,
50 µm.
Finally, regarding somatostatin-expression, cell bodies were
mostly present in the ePL (Figure 6A) and only occasionally in
the GrL (Figure 6C). Cell bodies degenerate with the disease
leaving cell debris (Figure 6A vs. Figure 6B and Figure 6C vs.
Figure 6D). To address, if cell bodies and/or fibers were reduced
in different degree, we quantified the % of area within each region
of interest occupied by somatostatin labeling (including cell
bodies plus fibers) and total somatostatin positive cell bodies in
the ePL. In this area, the reduction in % of area occupied by fibers
and cell bodies starts early (at 30 weeks of age) and the reduction
of somatostatin cell bodies is even sooner (at 16 weeks of age),
suggesting that soluble pathology focuses on cell bodies (see
discussion) (Figure 6E). Analysis of positive fibers and cells in the
ePL [Two-way ANOVA (genotype vs. age): Interaction F(3, 27) =
2.308; p = 0.0990; Age F(3, 27) = 0.8809; p = 0.4633; Genotype
F(1, 27) = 10.61; p = 0.0030], GrL [Two-way ANOVA (genotype
vs. age): Interaction F(3, 27) = 2.027; p = 0.1338; Age F(3, 27) =
2.864; p = 0.0552; Genotype F(1, 27) = 22.68; p < 0.0001] and
cell bodies in the ePL [Two-way ANOVA (genotype vs. age):
Interaction F(3, 27) = 0.9887; p= 0.4129; Age F(3, 27) = 7.861; p=
0.0006; Genotype F(1, 27) = 71.01; p < 0.0001] reveal significant
lower expression in transgenic vs. control animals (Figure 6E).
Further, in transgenic animals, a significant decrease with aging
was observed in the expression of fibers and cells in the GrL
[Two-way ANOVA (genotype vs. age): Interaction F(3, 27) =
FIGURE 4 | Vulnerability analysis of parvalbumin-expressing cells in
the olfactory bulb. (A–D), confocal images showing parvalbumin-positive
cells in the mitral/external plexiform layer of control and transgenic animals at
different ages. (E), Graphics illustrating the estimation of parvalbumin-positive
cells/mm3 in control and transgenic animals in the mitral/external plexiform
layer with aging. Calibration bar, 50 µm. White arrows point to labeled cells.
*P < 0.05.
2.027; p = 0.1338; Age F(3, 27) = 2.864; p = 0.0552; Genotype
F(1, 27)= 22.68; p< 0.0001] and in the expression of cell bodies in
the ePL [Two-way ANOVA (genotype vs. age): Interaction F(3, 27)
= 0.9887; p= 0.4129; Age F(3, 27) = 7.861; p= 0.0006; Genotype
F(1, 27) = 71.01; p< 0.0001] (Figures 6E–G).
Analysis of Aβ
As expected in the transgenic model, Aβ aggregation increased
over time, but mostly restricted to the granule cell layer
(Figures 7A–E). Percentage of area occupied by Aβ within GrL
was significantly increased from 16 and 30 weeks vs. 43 and 56
weeks and from 43 to 56 weeks (Figure 7F) [One way ANOVA
age: F(3, 13) = 91.87, p< 0.0001].
Co-localization of Aβ, Interneuron Markers,
and BrdU
Since analysis of interneuron vulnerability revealed that
calretinin-positive and, particularly, somatostatin-positive cells
were decreased in transgenic animals, additional colocalization
experiments were carried out to provide qualitative observations
(see Supplementary Figure 2). Examples of somatostatin-positive
cells with a dystrophic appearance (Supplementary Figure
2A) were placed in Aβ plaques (Supplementary Figure 2B)
surrounded by Aβ aggregates (Supplementary Figure 2C).
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FIGURE 5 | Vulnerability analysis of calretinin-expressing cells in the
olfactory bulb. (A–F) , confocal images showing calretinin-positive cells in the
different layers of control and transgenic animals at distinct ages. (G), graphics
illustrating the estimation of calretinin-positive cells/mm3 in control and
transgenic animals in the different layers with aging. Calibration bar, 50 µm.
*P < 0.05, **P < 0.01, ***P < 0.001.
Calretinin-positive cells (Supplementary Figure 2D) were also
located in Aβ plaques (Supplementary Figures 2E,F).
The low rate of BrdU-labeled cells coexpressing interneuron
markers prevented to carry out quantitative analysis. Only a small
percentage of them were observed co-expressing somatostatin
or calretinin (Supplementary Figure 3) and amyloid β (see
Supplementary Figure 4).
DISCUSSION
In the present report, neurogenesis, neurodegeneration,
interneuron vulnerability, and amyloid β involvement has been
investigated in theOB ofmousemodel of AD and control animals
over time. The main results include: neurogenesis increases with
aging in the granule cell layer of control animals from 16 to 43
weeks. No neurodegeneration changes have been observed after
quantifying NeuN or PGP9.5. Calbindin-expressing neurons
remains unchanged. Parvalbumin-expressing neurons trend to
increase with aging in transgenic animals. Calretinin-expressing
neurons increase with aging in transgenic mice in the GrL and
FIGURE 6 | Vulnerability analysis of somatostatin-expressing cells and
fibers in the olfactory bulb. (A–D), Confocal images showing
somatostatin-positive cells and fibers in the different layers of control and
transgenic animals at distinct ages. (E–G), graphics illustrating both % of area
occupied by somatostatin cell bodies and fibers within ePL and GrL and the
estimation of total somatostatin-positive in the ePL (cells/mm3) in control and
transgenic animals. Calibration bar, 50 µm. White arrows point to labeled cells.
Yellow arrow point to labeled periglomerular cell and yellow arrowheads to cell
debries. *P < 0.05, **P < 0.01, ***P < 0.001.
decrease in control animals in the ML and it is higher in control
as compared to transgenic animals at given ages. Somatostatin-
expressing neurons of transgenic mice decrease with aging and
abruptly as compared to controls. Amyloid β aggregates with
aging in the granule cell layer, which may be related to the
particular involvement of somatostatin-expressing cells.
Therefore, neurogenesis in transgenic animals, in contrast
to control animals, do not increase with aging. Regarding
interneuron vulnerability, calbindin expression is not altered,
parvalbumin expression is increased, calretinin increases in
transgenic and decreases in control animals and somatostatin
is strongly reduced with aging and in transgenic animals as
compared to controls. This evidences differential vulnerability
among interneuron pupulations which may be related to Aβ
pathology.
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FIGURE 7 | Amyloid β aggregation over time in the olfactory bulb of
transgenic animals. (A–D), %Aβ aggregates in transgenic mice at 16, 30,
43, and 56 weeks, respectively. (E), high power of a plaque. (F), graphics
illustrating % of area occupied by Aβ, virtually restricted to the granule cell layer.
Calibration bar for (A–D), 80 µm, for E, 20 µm. *P < 0.05, ****P < 0.0001.
Neurogenesis in Alzheimer’s Disease
Fifty years after the first seminal report of neurogenesis in the
adult brain (Altman and Das, 1965), the specific role of new-
born cells integrated in the DG (Kempermann et al., 2015) or
OB (Lepousez et al., 2015) is not fully understood. Growing
interest has focused on therapeutic opportunities, particularly
regarding neurodegenerative diseases, in particular Huntington’s,
Parkinson’s, and Alzheimer’s diseases (Kaneko and Sawamoto,
2009; Lazarov et al., 2010; Winner et al., 2011; Winner and
Winkler, 2015).
In the case of AD, there is a number of molecules implicated
in its etiology that also play a key role in adult neurogenesis
such as ApoE, PS1, APP, and its metabolites (Lazarov and
Marr, 2010; Mu and Gage, 2011). In particular, it has been
demonstrated that soluble APPα regulates neural progenitor cell
proliferation and that miscleavage of APP could greatly influence
in developmental and postnatal neurogenesis, which could
contribute to symptomatic cognitive deficits in AD (Lazarov and
Demars, 2012).
Data on neurogenic rates are quite variable depending on
species, age, environment, and disease. Neurogenesis occurs in
postnatal and adult rodents and postnatal humans (Lazarov
and Marr, 2013) but, in adult humans, there is substantial
hippocampal and striatal neurogenesis and it is no detectable in
the OB (Bergmann et al., 2015). There is a general agreement
regarding reduction of neurogenesis with aging (Hamilton et al.,
2013), which contrast with our present results in control animals.
In the granule cell layer, it has been described a decreasing
number of new-born cell with aging (Petrenau and Alvarez-
Buylla, 2002; Winner et al., 2002), which does not match our
results. It is interesting to note that previous reports show non-
significant peaks at 20 (Petrenau and Alvarez-Buylla, 2002) and
24 weeks (Winner et al., 2002) and ours results a significant peak
at 43 weeks. Likely these discrepancies are due methodological
differences regarding the method used: BrdU vs. [3H]-thymidine
or BrdU administration in 1 day vs. 4 consecutive days. In
diseased brains, however, data are highly variable depending
on the pathology analyzed. Even in AD, data are controversial
depending on model used, experimental conditions, markers or
area studied (Lazarov and Marr, 2010; Winner et al., 2011).
Reports in the double APP/PS1 transgenic model show a
reduced hippocampal neurogenesis. Niidome and colleagues
describe no reduction of proliferating cells in the SVZ, but a
significant decrease in the SGZ (Niidome et al., 2008). Verret
and colleagues report that, although hippocampal proliferation
was unaffected, survival of newborn cells 4 weeks later was
dramatically diminished (Verret et al., 2007). Conversely,
Demars and colleagues, conclude that this neurogenesis
impairment occurs early in life long before amyloid deposition
(Demars et al., 2010). Interestingly, it has been reported that the
reduction in neuroblasts was restricted to the hippocampal but
not to the OB neurogenic system (Zhang et al., 2007). In fact, our
results (Figure 1) show no significant reduction in the number
of BrdU-labeled cells in the glomerular layer in APP/PS1 model.
Amyloid β Proteinopathy and Interneuron
Population Involvement
Alzheimer disease is a neurodegenerative disease and as
such, neuronal loss is expected. It is difficult, however, to
distinguish neurodegenerative changes that accompany normal
aging (Attems et al., 2015) from those that characterize AD. In
the hippocampus, for instance, a significant cell loss was reported
in CA1 in Alzheimer’s patients, whereas there was almost no
neuron loss in the normal aging group (West et al., 1994). In the
OB, it has been reported that the total number of cells and the
number of mitral cells were the same for controls and patients,
but the volume of the bulb and the number of cells in the anterior
olfactory nucleus was reduced up to 75% in younger patients
(Ter Laak et al., 1994). Our results on the number of NeuN-
and PGP9.5-positive cells in the different layers of the bulb
reveal no neuronal loss with aging in both control and transgenic
mice suggesting that volume reduction must be due to neuropil
reorganization and shrinkage.
Amyloid β aggregation in the OB has been described as an
early event in the neuropathology of AD (Ohm and Braak, 1987;
Jellinger andAttems, 2005; Attems et al., 2012, 2014). In APP/PS1
mouse model, Aβ aggregation has been reported in the olfactory
cortex (Saiz-Sanchez et al., 2012) as well as in the OB and anterior
olfactory nucleus (Saiz-Sanchez et al., 2013). The present data
are in agreement with these reports showing an accumulative
aggregation of Aβ plaques in the OB, but restricted to the granule
cell layer.
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It has been described that the different interneuron
populations show differential expression and vulnerability
in the disease as compared to controls in given areas (Iritani
et al., 2001; Saiz-Sanchez et al., 2016) and not in others (Leuba
et al., 1998). In human tissue, it has been reported a 50%
reduction in somatostatin expression in the anterior olfactory
nucleus matching a high co-localization with Aβ (Saiz-Sanchez
et al., 2010). In the piriform cortex, somatostatin and calretinin
expression was reduced showing high co-localization with
Aβ, whereas parvalbumin expression was increased (Saiz-
Sanchez et al., 2015) in agreement with our present results. It
is interesting to note that not only Aβ aggregates, but soluble
Aβ—not detected with the used antibody—is particularly toxic
for neurons. Other authors describes that calretinin-positive
cells are resistant to neurodegeneration in the human temporal
cortex (Fonseca and Soriano, 1995)—which matches the light
increase described herein—and other authors reports differential
vulnerability of parvalbumin-positive cells depending on the
hippocampal field (Brady and Mufson, 1997) or entorhinal
cortex (Solodkin et al., 1996; Mikkonen et al., 1999). In the
olfactory cortex of APP/PS1 model, similar results were found
being somatostatin and calretinin expression severely reduced
and calbindin and parvalbumin expression later and only
moderately reduced (Saiz-Sanchez et al., 2012). It is interesting
to note that previous reports in our laboratory (Saiz-Sanchez
et al., 2012, 2013) studied groups up to 8 months of age, whereas
in the present report these observations were extended up to 56
weeks. Therefore, present data are in agreement with previous
reports and enlarge previous descriptions reveling, for instance,
a late increase of parvalbumin expression that could constitute
a compensatory mechanism of some calcium binding protein
expressing interneuron populations. In the OB, previous results
were similar (Saiz-Sanchez et al., 2013) and in agreement with
present data were calretinin- and, particularly somatostatin-,
expression was reduced in transgenic as compared to control
animals.
Regarding Alzheimer’s etiology, it has been described that
decreased somatostatin expression may predispose to Aβ
accumulation. This finding has raised the possibility that
somatostatin receptor agonists may be of therapeutic value in AD
(Hama and Saido, 2005; Iwata et al., 2005; Saito et al., 2005; Saido
and Iwata, 2006). The present results further support the idea
that somatostatin expressing neurons are early and preferentially
involved by Aβ pathology in AD and that this could be on its
etiology.
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